Systemic adverse effects of beta-adrenergic blockers: An evidence-based assessment

American Journal of Ophthalmology

Volumn 134, Issue 5, 2002, Pages 749-760

  Lama, Paul J ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PROPRANOLOL;

ANTIARRHYTHMIC ACTIVITY; ASTHMA; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CLAUDICATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG ACTIVITY; DRUG SAFETY; FATIGUE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; LIPID METABOLISM; LUNG DISEASE; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; NEUROMUSCULAR TRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEER REVIEW; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; VASCULAR DISEASE;

EID: 0036846934     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01699-9     Document Type: Article

References (91)

1. Musini A., Fabri B., Bergamaschi M., et al. Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am J Ophthalmol. 72:1971;773-781.
2. Alm A., Widengard I., Kjellgren D. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning a comparison with timolol . Ophthalmology. 102:1995;1743-1752.
3. Camras C.B. Comparison of latanorost and timolol in patients with ocular hypertension and glaucoma a six-month masked multicenter trial in the United States . Ophthalmology. 103:1996;138-147.
4. Watson P., Stjernschantz J., Latanoprost Study Group . A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103:1996;126-137.
5. Oparil S. Arterial hypertension. Bennett J.C., Plum F., Cecil textbook of medicine. 20th ed. 1996;264-266 W.B. Saunders & Co, Philadelphia.
6. Vander Zanden J.A., Valuck R.J., Bunce C.L., et al. Systemic adverse effects of ophthalmic beta-blockers. Ann Pharmacother. 35:2001;1633-1637.
7. Weisse A.B. The staff and the serpent. Pertinent and impertinent observations in the field of medicine. 1998;Southern Illinois University Press, Carbondale, IL.
8. Waagstein F., Hjalmarson A., Varnauskas E., et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1036.
9. Teerlink J.R., Massie B.M. Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol. 84:1999;94R-102R.
10. CIBIS II Investigators and Committees . The cardiac insufficiency bisoprolol study II (CIBIS II). Lancet. 353:1999;9-13.
11. MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF) . Lancet. 353:1999;2001-2007.
12. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 334:1996;1349-1355.
13. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
14. Beta-Blocker Evaluation of Survival Trial Investigators . A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 344:2001;1659-1667.
15. Berger R., Strecker K., Hulsmann M., et al. Experience with beta-blocker therapy in patients with advanced heart failure evaluated for Htx. J Heart Lung Transplant. 19:2000;1081-1088.
16. Haft J. Cardiovascular injury induced by catcholamines. Prog Cardiovasc Dis. 17:1974;73-85.
17. Gavras H., Kremer D., Brown J.J., et al. Angiotensin and norepinephrine-induced myocardial lesions experimental and clinical studies in rabbits and man . Am Heart J. 89:1975;321-332.
18. Squire I.B., Barnett D.B. The rational use of beta-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy. Br J Clin Pharmacol. 49:2000;1-9.
19. Hjalmarson A., Elmfeldt D.J.H., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double blind randomised trial. Lancet. 2:1981;823-827.
20. MIAMI Trial Research Group . Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 6:1985;199-226.
21. First International Study on Infarct Survival Collaborative Group . Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction ISIS-1. First international study of infarct survival collaborative group . Lancet. 2:1986;823-827.
22. de Muinck E.D., Li K.I. Safety and efficacy of beta-blockers in the treatment of stable angina pectoris. J Cardiovasc Pharmacol. 16:1990;S123-S128.
23. Bigger J.T. Jr. Cardiac arrhythmias. Bennett J.C., Plum F., Cecil textbook of medicine. 20th ed. 1996;231-253 W.B. Saunders & Co, Philadelphia.
24. Thadhani U., Whitsett T.L. beta-adrenergic blockers and intermittent claudication. Time for reappraisal. Arch Intern Med. 151:1991;1705-1707.
25. Lepantalo M., Lindstrom B.L., Totterman K.J. Adrenoceptor blocking dugs and cold feet in intermittent claudication. Vasa. 15:1986;135-137.
26. Bogaert M.G., Clement D.L. Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication. Eur Heart J. 4:1983;203-204.
27. Reichert M.D., Shibolet S., Adar R., Gafni J. Controlled trial of propranolol in intermittent claudication. Clin Pharmacol Ther. 17:1975;612-615.
28. Svendsen T.L., Jelnes R., Tonneson K.H. The effects of acebutolol and metoprolol on walking distance and distal blood pressure in hypertensive patients with intermittent claudication. Acta Med Scand. 219:1985;161-165.
29. Radack K., Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Inter Med. 151:1991;1769-1776.
30. Juhlin-Dannfelt A., Astrom H. Influence of beta-adrenoreceptor blockade on leg blood flow and lactate release in man. Scand J Clin Lab Invest. 39:1979;179-183.
31. Drazen J.M. Asthma. Bennett J.C., Plum F., Cecil textbook of medicine. 20th ed. 1996;376-381 W. B. Saunders & Co, Philadelphia.
32. Odeh M., Oliven A., Bassan H. Timolol eyedrop-induced fatal brochospasm in an asthmatic patient. J Fam Pract. 32:1991;97-98.
33. Taniguchi M., Kino H., Mori M., Nakahama M. A case of fatal asthma induced by timolol eyedrop. Jpn J Thoracic Dis. 28:1990;156-159.
34. Ananthanarayan C.R., Vaile S.J., Feldman F. Acute episode of asthma following topical administration of betaxolol eyedrops. Can J Ophthalmol. 28:1993;80-81.
35. Schoene R.B., Martin T.R., Charan N.B., French C.L. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA. 245:1981;1460-1461.
36. Inamizu T., Yoshikawa M., Murai H. A case of severe bronchial asthma following first use of timolol ophthalmic solution. Jpn J Thoracic Dis. 31:1993;385-389.
37. Belvisi M. Beta-blocker induced asthma a role for sensory nerve hyper-responsiveness? Clin Exp Allergy. 26:1996;1428-1435.
38. Hugues F.C., Le Jeunne C., Munera Y., Dufier J.L. Evaluation of systemic effects of timolol maleate in eye drops. J Francais d'Ophthalomologie. 8:1985;389-394.
39. Salpeter S., Ormiston T. E. S. Cardioselective beta-blocker use in patients with reversible airway disease. Cochrane Database Syst Rev. 3:2001;CD002992.
40. Matthay R.A., Arroliga A.C. Chronic airways disease. Bennett J.C., Plum F., Cecil textbook of medicine. 20th ed. 1996;381-389 W.B. Saunders & Co, Philadelphia.
41. Woolcock A.J., Anderson S.D., Peat J.K., et al. Characteristics of bronchial hyper-responsiveness in chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis. 143:1991;1438-1443.
42. Sherwin R.S. Diabetes Mellitus. Bennett J.C., Plum F., Cecil textbook of medicine. 20th ed. 1996;1271-1272 W.B. Saunders & Co, Philadelphia.
43. Molnar G.W., Read R.C., Wright F.E. Propranolol enhancement of hypoglycemic sweating. Clin Pharmaco Ther. 15:1974;490-496.
44. United Kingdom Prospective Diabetes Study Group . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. BMJ. 317:1998;713-720.
45. Shorr R.S., Ray W.A., Daugherty J.R., Griffin M.R. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 278:1997;40-43.
46. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results II The relationship of reduction in incidence of coronary heart disease to cholesterol lowering . JAMA. 251:1984;365-374.
47. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 76:1995;10-17.
48. Kjekshus J., Pederson T. Reducing the risk of coronary events Evidence from the Scandinavian Simvastatin Survival Study (4S) . Am J Cardiol. 76:1995;64-68.
49. Probstfield J.E., Margitic S.E., Byington R.P., et al. Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study. Am J Cardiol. 76:1995;47-53.
50. Madu E.C., Reddy R.C., Madu A.N., et al. Review The effects of antihypertensive agents on serum lipids . Am J Med Sci. 312:1996;76-84.
51. Rabkin S.W., Huff M.W., Newman C., et al. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized double-blind trial The Alpha Beta Canada Study . Hypertension. 24:1994;241-248.
52. Multiple Risk Factor Intervention Trial Group . Multiple risk factors intervention trial-risk factor changes and mortality results. JAMA. 248:1982;1465-1477.
53. Witzlum J.L., Steinberg D. The hyperlipoproteinemias. Bennett J.C., Plum F., Cecil textbook of medicine. 20th ed. 1996;1086-1095 W. B. Saunders & Co, Philadelphia.
54. Durington P., Brownlee W., Large D. Short-term effects of beta-adrenoreceptor blocking drugs with and without cardioselectivity and intrinsic sympathomimetic activity on lipoprotein metabolism and hypertriglyceridemic patients and normal men. Clin Sci. 69:1985;713-719.
55. Lakshman R., Reda D.J., Materson B.J., et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med. 159:1999;551-558.
56. Coleman A.L., Diehl D.L.C., Jampel H.D., et al. Topical timolol decreases plana high-density lipoprotein cholesterol level. Arch Ophthalmol. 108:1990;1260-1263.
57. Stewart W.C., Dubiner H.B., Mundorf T.K., et al. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol. 127:1999;142-147.
58. Bartlett J., Olivier M., Richardson T., et al. Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women. J Glaucoma. 8:1999;388-395.
59. Freedman S.F., Freedman N.F., Shields M.B., et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol. 116:1993;600-611.
60. Stampfer M.J., Sacks F.M., Salvini S., et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 325:1991;371.
61. Yudofsky S.C. Beta-blockers and depression. The clinician's dilemma. JAMA. 267:1992;1826-1827.
62. Waal H.J. Propranolol-induced depression. BMJ. 2:1967;50.
63. Kohn R.J. Beta-blockers an important cause of depression a medical myth without evidence . Med Health RI. 84:2001;92-95.
64. Petrie W.M., Maffucci R.J., Woolsey R.L. Propranolol and depression. Am J Psychiatry. 139:1982;92-94.
65. Pollack M.H., Rosenbaum J.F., Cassem N.H. Propranolol and depression revisited three cases and a review . J Nerv Ment Dis. 173:1985;118-119.
66. Avorn J., Everitt D.E., Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA. 255:1986;357-360.
67. Thiessen B.Q., Wallace S.M., Blackburn J.L., et al. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med. 150:1990;2286-2290.
68. Bright R.A., Everitt D.E. Beta-blockers and depression evidence against an association. JAMA. 267:1992;1783-1787.
69. Gerstmann B.B., Jolson H.M., Bauer M., et al. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol. 49:1996;809-815.
70. Hallas J. Evidence of depression provoked by cardiovascular medication a prescription sequence analysis . Epidemiology. 7:1996;478-484.
71. Paauw D.S. Did we learn evidenced-based medicine in medical school? Some common medical mythology. J Am Board Fam Prac. 12:1999;143-149.
72. Zelnik T. Depressive effects of drugs. 1987;John Wiley & Sons, New York.
73. Prisant L.M., Carr A.A., Bottini P.B., et al. Sexual dysfunction with hypertensive drugs. Arch Intern Med. 154:1994;730-736.
74. Grimm R.H., Grandits G.A., Prineas R.J., et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 29:1997;8-14.
75. Perez-Stable E.J., Halliday R., Gardiner P.S. The effects of propranolol on cognitive function and quality of life a randomized trial among patients with diastolic hypertension . Am J Med. 108:2000;359-365.
76. Duncan J.J., Vaandrager H., Farr J.E., et al. Effect of intrinsic sympathomimetic activity on the ability of hypertensive patient's cardiorespiratory training effect receiving chronic beta-blockade. Am J Hypertens. 3:1990;302-306.
77. Gordon N.F., Duncan J.J. Effect of beta-blockers on exercise physiology implications for exercise training . Med Sci Sports Exercise. 23:1991;668-676.
78. Vanhees L., Defoor J.G., Schepers D., et al. Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men. J Hypertens. 18:2000;35-43.
79. Gullestad L., Hallen J., Medbo J.I., et al. The effect of acute versus chronic treatment with beta-adrenoceptor blockade on exercise performance, haemodynamic, and metabolic parameters in healthy men and women. Br J Clin Pharmacol. 41:1996;57-67.
80. Epstein S.E., Robinson B.F., Kahler R.L. Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest. 44:1965;1745-1753.
81. Joyner M.J., Freund B.J., Jilka S.A., et al. Effects of beta blockade on exercise capacity of trained and untrained men a hemodynamic comparison . J Appl Physiol. 60:1986;1429-1434.
82. Sklar J., Johnston G.D., Overlie P. The effects of a cardioselective (metoprolol) and a nonselective (propranolol) beta-adrenergic blocker on the response to exercise in normal men. Circulation. 65:1982;894-899.
83. Mora-Rodriguez R., Hodgkinson B.J., Byerley L.O., Coyle E.F. Effects of beta-adrenergic receptor stimulation and blockade on substrate metabolism during submaximal exercise. Am J Physiol Endocrinol Metab. 280:2001.
84. Wislicki L., Rosenblum L. Effects of propranolol on the action of neuromuscular blocking drugs. Br J Anaesth. 39:1967;939-942.
85. Herishanu Y., Rosenberg P. Beta-blockers and myasthenia gravis. Ann Intern Med. 83:1975;834-835.
86. Vuori M.L., Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Arch Clin Exp Ophthalmol. 233:1995;131-134.
87. Physician's desk reference. 53rd ed. 1999;1741 Medical Economics Co, Montvale, NJ.
88. Bobik A., Jennings G.L., Asley P., et al. Timolol pharmacokinetics and effects on heart rate and blood pressure after acute and chronic administration. Eur J Clin Pharmacol. 16:1979;243-249.
89. Wilson T.W., Fior W.B., Johnson G.E., et al. Timolol and propranolol bioavailability, plasma concentration, and beta blockade . Clin Pharmacol Ther. 32:1982;676-685.
90. Shedden A., Laurence J., Tipping R., et al. Efficacy and tolerability of timolol maleate gel-forming solution versus timolol ophthalmic solution in adults with open angle glaucoma and ocular hypertension a 6-month, double-masked, multicenter study . Clin Ther. 23:2001;440-450.
91. Fourtillan J.B., Courtois P., Levebvre M.A., et al. Pharmacokinetics of oral timolol studied by mass fragmentography. Eur J Clin Pharmacol. 19:1981;193-196.